Advertisement

Geschlechtsspezifische Unterschiede bei chronisch-entzündlichen Darmerkrankungen

  • I. Blumenstein
  • B. SiegmundEmail author
  • E. Sonnenberg
Schwerpunkt

Zusammenfassung

Die vorliegende Übersichtsarbeit gibt einen Überblick über die aktuelle Studienlage zu geschlechtsspezifischen Unterschieden in der Behandlungsrealität von Patienten mit chronisch-entzündlichen Darmerkrankungen. Hierbei wird auf den Krankheitsverlauf, die medikamentöse und chirurgische Therapie, psychosoziale Unterschiede sowie auf Besonderheiten der medikamentösen Therapie in Schwangerschaft und Stillzeit eingegangen.

Schlüsselwörter

Geschlecht  Schwangerschaft CED Entzündung Biologika 

Gender-specific differences in inflammatory bowel disease

Abstract

This review provides an overview on current data regarding gender-specific differences in patients with inflammatory bowel diseases. The focus will be on disease course, medical as well as surgical treatment strategies, psychosocial differences and special requirements regarding drug therapy during pregnancy and nursing.

Keywords

Sex  Pregnancy IBD Inflammation Biologicals 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

I. Blumenstein, B. Siegmund und E. Sonnenberg geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Hausmann J, Blumenstein I (2015) Gender differences and inflammatory bowel disease. Z Gastroenterol 53(8):774–778PubMedGoogle Scholar
  2. 2.
    Brahme F, Lindstrom C, Wenckert A (1975) Crohn’s disease in a defined population. An epidemiological study of incidence, prevalence, mortality, and secular trends in the city of Malmo, Sweden. Baillieres Clin Gastroenterol 69(2):342–351Google Scholar
  3. 3.
    Kyle J (1992) Crohn’s disease in the northeastern and northern Isles of Scotland: an epidemiological review. Baillieres Clin Gastroenterol 103(2):392–399Google Scholar
  4. 4.
    Latour P, Louis E, Belaiche J (1998) Incidence of inflammatory bowel disease in the area of Liege: a 3 years prospective study (1993–1996). Acta Gastroenterol Belg 61(4):410–413PubMedGoogle Scholar
  5. 5.
    Leong RW, Lau JY, Sung JJ (2004) The epidemiology and phenotype of Crohn’s disease in the Chinese population. Inflamm Bowel Dis 10(5):646–651PubMedGoogle Scholar
  6. 6.
    Ng SC et al (2013) Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 62(4):630–649PubMedGoogle Scholar
  7. 7.
    Shivananda S et al (1987) Epidemiology of Crohn’s disease in Regio Leiden, The Netherlands. A population study from 1979 to 1983. Baillieres Clin Gastroenterol 93(5):966–974Google Scholar
  8. 8.
    Wagtmans MJ et al (2001) Gender-related differences in the clinical course of Crohn’s disease. Am J Gastroenterol 96(5):1541–1546PubMedGoogle Scholar
  9. 9.
    Yang SK, Loftus EV Jr., Sandborn WJ (2001) Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 7(3):260–270PubMedGoogle Scholar
  10. 10.
    Virta L et al (2012) Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease—a nationwide, register-based finnish case-control study. Am J Epidemiol 175(8):775–784PubMedGoogle Scholar
  11. 11.
    Shaw SY, Blanchard JF, Bernstein CN (2010) Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 105(12):2687–2692PubMedGoogle Scholar
  12. 12.
    Andersson RE et al (2003) Appendectomy is followed by increased risk of Crohn’s disease. Baillieres Clin Gastroenterol 124(1):40–46Google Scholar
  13. 13.
    Lakatos PL, Szamosi T, Lakatos L (2007) Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 13(46):6134–6139PubMedPubMedCentralGoogle Scholar
  14. 14.
    Lakatos PL et al (2013) Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 19(5):1010–1017PubMedGoogle Scholar
  15. 15.
    Biedermann L et al (2015) High rates of smoking especially in female Crohn’s disease patients and low use of supportive measures to achieve smoking cessation—data from the Swiss IBD cohort study. J Crohns Colitis 9(10):819–829PubMedGoogle Scholar
  16. 16.
    Fraga M et al (2017) Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur J Gastroenterol Hepatol 29(1):91–97PubMedGoogle Scholar
  17. 17.
    Ampuero J et al (2014) Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol 29(2):291–295PubMedGoogle Scholar
  18. 18.
    Greenstein AJ et al (1992) Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 71(5):261–270Google Scholar
  19. 19.
    Wu XR et al (2013) Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohns Colitis 7(5):e171–7PubMedGoogle Scholar
  20. 20.
    Vavricka SR et al (2012) Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 18(3):496–505PubMedGoogle Scholar
  21. 21.
    Lee DW et al (2017) Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery. World J Gastroenterol 23(35):6474–6481PubMedPubMedCentralGoogle Scholar
  22. 22.
    Romberg-Camps MJ et al (2009) Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 104(2):371–383PubMedGoogle Scholar
  23. 23.
    Mazor Y et al (2011) Prediction of disease complication occurrence in Crohn’s disease using phenotype and genotype parameters at diagnosis. J Crohns Colitis 5(6):592–597PubMedGoogle Scholar
  24. 24.
    Blumenstein I et al (2011) Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis 5(3):203–210PubMedGoogle Scholar
  25. 25.
    Bokemeyer B et al (2013) Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis 7(5):355–368PubMedGoogle Scholar
  26. 26.
    Wada Y et al (2015) Risk factors for decreased bone mineral density in inflammatory bowel disease: a cross-sectional study. Clin Nutr 34(6):1202–1209PubMedGoogle Scholar
  27. 27.
    Walldorf J et al (2013) Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohns Colitis 7(11):901–907PubMedGoogle Scholar
  28. 28.
    Bartram SA et al (2006) Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn’s disease. World J Gastroenterol 12(35):5680–5686PubMedPubMedCentralGoogle Scholar
  29. 29.
    Robinson RJ et al (1998) Osteoporosis and determinants of bone density in patients with Crohn’s disease. Dig Dis Sci 43(11):2500–2506PubMedGoogle Scholar
  30. 30.
    Soderlund S et al (2010) Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Baillieres Clin Gastroenterol 138(5):1697–1703Google Scholar
  31. 31.
    Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10(6):639–645PubMedGoogle Scholar
  32. 32.
    Bessissow T et al (2013) Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. J Crohns Colitis 7(11):e580–e587PubMedGoogle Scholar
  33. 33.
    Thukkani N, Williams JL, Sonnenberg A (2011) Epidemiologic characteristics of patients with inflammatory bowel disease undergoing colonoscopy. Inflamm Bowel Dis 17(6):1333–1337PubMedGoogle Scholar
  34. 34.
    Koido S et al (2014) Factors associated with incomplete colonoscopy at a Japanese academic hospital. World J Gastroenterol 20(22):6961–6967PubMedPubMedCentralGoogle Scholar
  35. 35.
    Rimola J et al (2009) Role of 3.0-T MR colonography in the evaluation of inflammatory bowel disease. Radiographics 29(3):701–719PubMedGoogle Scholar
  36. 36.
    Caso V et al (2010) Gender differences in patients with acute ischemic stroke. Womens Health (Lond) 6(1):51–57Google Scholar
  37. 37.
    Shaw LJ et al (2008) Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 117(14):1787–1801PubMedGoogle Scholar
  38. 38.
    Lesuis N et al (2012) Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med 10:82PubMedPubMedCentralGoogle Scholar
  39. 39.
    Oliver JE, Silman AJ (2009) Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther 11(5):252PubMedPubMedCentralGoogle Scholar
  40. 40.
    Szalat A, Raz I (2008) Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab 10(12):1135–1156PubMedGoogle Scholar
  41. 41.
    Schmetzer O, Florcken A (2012) Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol 2012(214):411–442Google Scholar
  42. 42.
    Billioud V, Sandborn WJ, Peyrin-Biroulet L (2011) Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 106(4):674–684PubMedGoogle Scholar
  43. 43.
    Sprakes MB et al (2012) Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: a large single centre experience. J Crohns Colitis 6(2):143–153PubMedGoogle Scholar
  44. 44.
    Zelinkova Z et al (2012) Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J Gastroenterol 18(47):6967–6973PubMedPubMedCentralGoogle Scholar
  45. 45.
    Lie MR, Kreijne JE, van der Woude CJ (2017) Sex is associated with adalimumab side effects and drug survival in patients with Crohn’s disease. Inflamm Bowel Dis 23(1):75–81PubMedGoogle Scholar
  46. 46.
    Hawthorne AB, Rubin G, Ghosh S (2008) Review article: medication non–adherence in ulcerative colitis—strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 27(12):1157–1166PubMedGoogle Scholar
  47. 47.
    Long MD et al (2012) Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis 18(11):2099–2106PubMedGoogle Scholar
  48. 48.
    Mantzaris GJ et al (2007) How adherent to treatment with azathioprine are patients with Crohn’s disease in long-term remission? Inflamm Bowel Dis 13(4):446–450PubMedGoogle Scholar
  49. 49.
    Yen L et al (2012) Medication use patterns and predictors of nonpersistence and nonadherence with oral 5‑aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm 18(9):701–712PubMedGoogle Scholar
  50. 50.
    Zelante A et al (2014) Adherence to medical treatment in inflammatory bowel disease patients. Minerva Gastroenterol Dietol 60(4):269–274PubMedGoogle Scholar
  51. 51.
    Lopez A et al (2013) Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 19(7):1528–1533PubMedGoogle Scholar
  52. 52.
    Peyrin-Biroulet L et al (2012) Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol 107(11):1693–1701PubMedPubMedCentralGoogle Scholar
  53. 53.
    Hofer B et al (2001) The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn’s disease. Hepatogastroenterology 48(37):152–155PubMedGoogle Scholar
  54. 54.
    De Cruz P et al (2015) Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients—a POCER study analysis. Aliment Pharmacol Ther 42(7):867–879PubMedGoogle Scholar
  55. 55.
    Samuel S et al (2013) Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 19(9):1858–1866PubMedPubMedCentralGoogle Scholar
  56. 56.
    Targownik LE et al (2012) The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 107(8):1228–1235PubMedGoogle Scholar
  57. 57.
    Rottoli M et al (2012) Gender of the patient may influence perioperative and long-term complications after restorative proctocolectomy. Colorectal Dis 14(3):336–341PubMedGoogle Scholar
  58. 58.
    Wu XR et al (2016) Male gender is associated with a high risk for chronic antibiotic-refractory pouchitis and ileal pouch anastomotic sinus. J Gastrointest Surg 20(3):631–639PubMedGoogle Scholar
  59. 59.
    Sewitch MJ et al (2001) Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol 96(5):1470–1479PubMedGoogle Scholar
  60. 60.
    Slonim-Nevo V et al (2018) Effect of social support on psychological distress and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis 24(7):1389–1400PubMedGoogle Scholar
  61. 61.
    Fuller-Thomson E, Sulman J (2006) Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 12(8):697–707PubMedGoogle Scholar
  62. 62.
    Hauser W et al (2011) Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis 17(2):621–632PubMedGoogle Scholar
  63. 63.
    Nahon S et al (2012) Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis 18(11):2086–2091PubMedGoogle Scholar
  64. 64.
    Panara AJ et al (2014) The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharmacol Ther 39(8):802–810PubMedGoogle Scholar
  65. 65.
    Maunder RG et al (1997) Health-related concerns of people who receive psychological support for inflammatory bowel disease. Can J Gastroenterol 11(8):681–685PubMedGoogle Scholar
  66. 66.
    Graff LA et al (2006) The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 4(12):1491–1501PubMedGoogle Scholar
  67. 67.
    Hauser G et al (2011) Gender related differences in quality of life and affective status in patients with inflammatory bowel disease. Coll Antropol 35(Suppl 2):203–207PubMedGoogle Scholar
  68. 68.
    Nurmi E et al (2013) The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J Gastroenterol 48(1):51–57PubMedGoogle Scholar
  69. 69.
    McDermott E et al (2015) Body image dissatisfaction: clinical features, and psychosocial disability in inflammatory bowel disease. Inflamm Bowel Dis 21(2):353–360PubMedGoogle Scholar
  70. 70.
    Shin T, Okada H (2016) Infertility in men with inflammatory bowel disease. World J Gastrointest Pharmacol Ther 7(3):361–369PubMedPubMedCentralGoogle Scholar
  71. 71.
    Allocca M et al (2018) Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol 30(3):316–322PubMedGoogle Scholar
  72. 72.
    Heetun ZS et al (2007) Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther 26(4):513–533PubMedGoogle Scholar
  73. 73.
    Mountifield R et al (2009) Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 15(5):720–725PubMedGoogle Scholar
  74. 74.
    Feagins LA, Kane SV (2009) Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol 104(3):768–773PubMedGoogle Scholar
  75. 75.
    de Lima A et al (2016) Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol 14(9):1285–1292PubMedGoogle Scholar
  76. 76.
    Sands K et al (2015) Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther 41(9):821–834PubMedGoogle Scholar
  77. 77.
    Selinger CP et al (2013) Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis 7(6):e206–13PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Zentrum der Inneren Medizin, Medizinische Klinik 1, Schwerpunkt Gastroenterologie, Hepatologie, Universitätsklinikum FrankfurtGoethe-Universität Frankfurt am MainFrankfurt am MainDeutschland
  2. 2.Campus Benjamin Franklin, Medizinische Klinik mit Schwerpunkt Gastroenterologie, Infektiologie, RheumatologieCharité – Universitätsmedizin Berlin, „corporate member“ der Freien Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of HealthBerlinDeutschland

Personalised recommendations